JC03 Rec'd PCT/PTO 1 4 NOV2004

Attorney Docket No. PC27365

Thereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 11th day of November, 2005.

NOV 1 4 2005 W

(Signature of person mailing)

Carol A. Senn

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

DANILO GIRIBONE, ET AL.

APPLICATION NO.:

10/540,081

Examiner: Not Yet Assigned

FILING DATE:

JUNE 16, 2005

Group Art Unit: 1614

TITLE: STABLE ISOTOPE-LABELED

CAMPTOTHECIN DERIVATIVES

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12). A copy of the International Search Report from counterpart International Application No. PCT/EP03/14801 is also enclosed.

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited.

Respectfully submitted

Date: November 11, 2005

David L. Kershner

Attorney for Applicant(s)

Reg. No. 53,112

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212) 733-0538

USERS\DOCS\LA21952\KERSHD\5GKL01!.DOC / 254757 / PC27365 INFO DISCL STMT 11/9/05

ſ		****									Ĭ					
INFORMATION DISCLOSURE CITATION							ATTY. DOCKET NO. PC27365					SERIAL NO. 10/540,081				
(Use several sheets if necessary)							APPLICANT DANILO GIRIBONE, ET AL.									
OIPE							FILING DATE JUNE 16, 2005				GROUP 1614					
ļ			, 		<u> </u>		PATENT	DOCU	MENTS							
EXAMINER NOV 1 4 2000 MINITIAL NOV 1 4 2000 MINITIAL						BER			DATE	NAME	CL	ASS	SUBCLASS FILING D		DATE F	
			The state of the s		£/				-					AFFRO	PRIATE	
<u> </u>	+	 	Are The	DEMARK	/											
	-				.											
	-															
												•				
					FO	REIG	N PATE	NT DO	CUMENTS	6						
DOCUMENT NUMBER									DATE	COUNTRY	CI	ASS	SUBCLASS	TRANSI	LATION	
										000,1111			0000000	VEC	T.,,	
														YES	NO	
wo_		4	0	5	6	3	9	8	7/8/04	PCT					-	
wo	1	0	1	2	1	2	1	9	2/29/01	PCT	-			ļ	1	
	 		OTHE	R DOCL	JMENTS	(Inclu	ıding Au	thor, Titi	le, Date, F	Pertinent Page	es, Etc.)					
			Slatter, J.G., et al., "Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) following I.V. Infusion of [14C]CPT-11 in Cancer Patients", Drug Metabolism & Disposition, 2000, Vol. 28, No. 4, pgs 423-433.													
		b!quin	Atsumi, R., et al., "Pharmacokinetics of SN-38 '(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano '3', 4':6,7!-indolizino '1,2-b!quinoline-3, 14(4H, 12H)-dione!, an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats." Biological & Pharmaceutical Bulletin, Aug. 1995, Vol. 18, No. 8, pgs 1114-1119.													
		Hinz, H.R., et al., "Stabilities of <3>H- and <2>H-labelled camptothecins", Journal of Labelled Compounds and Radiopharmaceuticals, 1996, Vol. 38, No. 8, pgs.733-742.														
	Ronman, P.E., et al., "The Preparation of Tritium Labeled Camptothecin and Deuterium Labeled Camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1981, Vol. 18, No. 3, pgs 319-330.															
	Emerson, D.L., et al., "Antitumor efficacy, pharmacokinetics, and biodistribution of NX211:a low clearance liposomal formulation of lurtotecan"., Clinical Cancer Research, July 2000, Vol. 6, No. 7, pgs 2903-2912.															
									amptothecin	and topotecan a	it normal a	nd a	cidic pH"., C	ancer	r	
	Research, Nov. 1997, Vol. 57, No. 21, pgs 4811-4816 Nicholas, A.W., et al., "Synthesis of position-specific tritium-labeled 20(S)-camptothecin, 9-amino-20(S)-camptothecin, and 10, 11-methylenedioxy-20(S)-camptothecin", Journal of Labelled Compounds and Radiopharmaceuticals, 1993, Vol. 33, No. 9, pgs 839-848													0, ogs		
EXAMINER /Charanjit Aulakh/							DATE CONSIDERED 04/29/2009									
		reference con ion to applica		ether or not cit	tation is in cont	formance	with MPEP 6	09; Draw line	through citation	if not in conformance	and not consi	dered.	include copy of	this for	m	

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

,USERS\DOCS\LA21952\KERSHD\5GKJ01!.DOC / 254755 / PC27365 INFO DISC CIT - 11/9/05

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/